Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31614821 | 0.80 | GAA (0.32) | GAACYP4F2CYP4A11PKMMAPT | |
| SCHEMBL30933494 | 0.79 | PKM (0.32) | GAAPKM | |
| SCHEMBL25434697 | 0.79 | PKM (0.32) | GAAPKM | |
| SCHEMBL17942337 | 0.78 | SHBG (0.34) | — | |
| SCHEMBL1571082 | 0.78 | GAA (0.36) | GAAMAPTKMT2A | |
| SCHEMBL286513 | 0.78 | CYP4F2 (0.33) | GAACYP4F2CYP4A11HTR2APDE4A | |
| SCHEMBL10717222 | 0.77 | GABRA1 (0.34) | PKMHTR2A | |
| SCHEMBL333557 | 0.77 | — | — | |
| SCHEMBL30014250 | 0.77 | GABRA1 (0.34) | PKMHTR2A | |
| SCHEMBL3414080 | 0.77 | MAPT (0.32) | GAAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503475-B2 | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2025-12-23 | — | — | US | disclosed |
| US-20250100968-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND RELATED USES | OXFORD FINANCE LLC | 2025-03-27 | — | — | US | disclosed |
| WO-2025038462-A2 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4486445-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND RELATED USES | Centessa Pharmaceuticals (UK) Limited (GB) | 2025-01-08 | — | — | EP | disclosed |
| CN-119156375-A | Bicyclic heterocyclic derivatives and related uses | 森特萨制药(英国)有限公司 | 2024-12-17 | — | — | CN | disclosed |
| WO-2023167865-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND RELATED USES | OREXIA THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023167865-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND RELATED USES | OREXIA THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | WO | disclosed |
| US-20230271973-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230271973-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230271973-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| CN-102666545-A | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors | CELLZOME LTD | 2012-09-12 | — | — | CN | disclosed |
| EP-2491039-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2012022681-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
| US-8097733-B2 | Pyrazole derivatives as 5-LO-inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
| CN-101918392-A | Pyrazole derivatives as 5-LO inhibitors | PFIZER | 2010-12-15 | — | — | CN | disclosed |
| EP-2225229-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | Pfizer Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | PFIZER INC. | 2009-09-10 | — | — | US | disclosed |
| WO-2009069044-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | PFIZER INC. (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503475-B2 | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | HCRTR2, HCRTR1, CRHR2 | GAA 1870/4885CYP4F2 211/4885CYP4A11 471/4885 |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | GAA 3325/4885CYP4F2 1917/4885CYP4A11 1734/4885 |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | ALOX5, ALOX15, CYP3A5 | GAA 1020/4885CYP4F2 31/4885CYP4A11 53/4885 |
| US-20230271973-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR2 | GAA 1870/4885CYP4F2 211/4885CYP4A11 471/4885 |
| US-20250100968-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND RELATED USES | HCRTR2, HCRTR1, CRHR1 | GAA 1022/4885CYP4F2 145/4885CYP4A11 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.